StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Equities research analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

A number of other analysts have also commented on the company. HC Wainwright reissued a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, eight have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Marinus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Stock Down 0.2 %

MRNS stock opened at $0.55 on Monday. The firm has a market cap of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. The business has a 50 day moving average of $0.54 and a 200 day moving average of $0.80. Marinus Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $9.69.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. World Investment Advisors LLC purchased a new position in shares of Marinus Pharmaceuticals in the 3rd quarter worth $104,000. Virtu Financial LLC purchased a new position in shares of Marinus Pharmaceuticals in the 4th quarter worth $36,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in shares of Marinus Pharmaceuticals in the 4th quarter worth $54,000. Jacobs Levy Equity Management Inc. boosted its stake in shares of Marinus Pharmaceuticals by 39.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 117,255 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Marinus Pharmaceuticals by 1,968.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 126,752 shares during the last quarter. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.